REDACTED vs UNION OF INDIA

Court
Kerala High Court

CNR : KLHC010381092022
1
W.P.(C) No.18999 of 2022 2026:KER:74251


IN THE HIGH COURT OF KERALA AT ERNAKULAM
PRESENT
THE HONOURABLE MR. JUSTICE HARISANKAR V. MENON
TH
MONDAY, THE 28 DAY OF SEPTEMBER 2026 / 6TH ASWINA, 1948

WP(C) NO. 18999 OF 2022
PETITIONER:

IN RE EXORBITANT PRICING OF LIFE SAVING

PATENTED MEDICINES.

(SUBSTITUTED AS PER ORDER DATED 16.09.2022)


BY SMT.MAITREYI SACHIDANANDA HEGDE, AMICUS CURIAE


RESPONDENTS:

1 UNION OF INDIA,
REPRESENTED BY SECRETARY, MINISTRY OF HEALTH
AND FAMILY WELFARE, GOVERNMENT OF INDIA, ROOM NO.348;
‘A’ WING, NIRMAN BHAVAN, NEW DELHI-110011.

2 SECRETARY, DEPARTMENT OF PHARMACEUTICALS,
MINISTRY OF CHEMICALS AND FERTILIZERS, GOVERNMENT OF INDIA,
236A, A- WING, 2ND FLOOR, SHASTRI BHAWAN,
DR.RAJENDRA PRASAD ROAD, NEW DELHI, PIN – 110001.

3 SECRETARY, DEPARTMENT FOR PROMOTION OF INDUSTRY
AND INTERNAL TRADE (DPIIT),
UDYOG BHAWAN, NEW DELHI, PIN – 110011.

4 SECRETARY, MINISTRY OF WOMEN AND CHILD DEVELOPMENT,
SHASTRI BHAWAN, DR. RAJENDRA PRASAD ROAD, NEW DELHI,
PIN – 110001.

5 CONTROLLER GENERAL OF PATENTS,
DESIGNS AND TRADE MARKS, PATENT OFFICE KOLKATA,
BOUDHIK SAMPADA BHAWAN, CP-2 SECTOR V, SALT LAKE CITY,
KOLKATA, PIN – 700091.

CNR : KLHC010381092022
2
W.P.(C) No.18999 of 2022 2026:KER:74251



6 INDIAN COUNCIL OF MEDICAL RESEARCH
REPRESENTED BY DIRECTOR-GENERAL,
ANSARI NAGAR, NEW DELHI, PIN – 110029.

ADDL.R7 RAHUL BAJAJ, 001, SARVAPRIYA VIHAR APARTMENTS,
NEW DELHI - 110016.

(ADDITIONAL R7 IS IMPLEADED AS PER ORDER DATED 02.09.2022 IN
I.A.NO.1/2022 IN WP(C) NO.18999/2022).

ADDL.R8 ELI LILLY COMPANY (INDIA) PVT. LTD.,
PLOT# 92, SECTOR 32, INSTITUTIONAL AREA, GURGAON - 122 001,
HARYANA, INDIA

[IS SUO MOTU IMPLEADED AS PER ORDER DATED 15.03.2023 IN
WP(C)NO.18999/2022]

ADDL.R9 NOVARTIS A G., LICHTRASSE 35, CH - 4056 BASEL,
SWITZERLAND.

(IS SUO MOTU IMPLEADED AS PER ORDER DATED 16.06.2023
IN WP(C) No.18999/2022).

ADDL.R10 M.RADHAKRISHNAN, S/O.KRISHNAMENON, AGED 74 YEARS,
RESIDING AT PRA 45A, MANDANATHU, PALLIPARAMBUKAVU ROAD,
TRIPUNITHURA, ERNAKULAM-682301.

[ADDL.R10 IS IMPLEADED AS PER ORDER DATED 19.10.2023 IN
I.A.NO.3/2023 IN WP(C)NO.18999/2022]

ADDL.R11 NATIONAL CANCER INSTITUTE, AIIMS, JHAJJAR, BADSA,
JHAJJAR, HARYANA, PIN-124105.

ADDL.R12 CHITTARANJAN NATIONAL CANCER INSTITUTE,
SHYAMA PRASAD MUKHERJEE ROAD, BAKUL BAGAN,
BHOWANIPORE, KOLKATA, WEST BENGAL, PIN-700 026.

ADDL.R13 REGIONAL CANCER CENTRE,
THIRUVANANTHAPURAM, KUMARAPURAM ROAD,
MEDICAL COLLEGE CAMPUS, CHALAKKUZHI, PIN-695 011.

ADDL.R14 THE DRUG CONTROLLER GENERAL OF INDIA
FDA BHAVAN, ITO, KOTLA ROAD, NEW DELHI,
PIN-110 002.

CNR : KLHC010381092022
3
W.P.(C) No.18999 of 2022 2026:KER:74251



[ADDL. R11 TO R14 ARE SUO MOTU IMPLEADED AS PER ORDER DATED
15.07.2026 IN WP(C) NO.18999/2022]

ADDL.R15 MAJIDA A.M., AGE 49, W/O. ADV. KHALEEMUDHEEN, RESIDING AT
PADINHARAKAM ENNA KOLLANAKAM, NEAR T I UP SCHOOL, PONNANI
NAGRAM, PONNANI, MALAPPURAM, KERALA- 679583.

[ADDL.R15 IS IMPLEADED AS PER ORDER DATED 21.08.2026 IN
I.A.NO.1/26 IN WP(C) NO.18999/22]

BY ADVS.
O.M.SHALINA, DEPUTY SOLICITOR GENERAL OF INDIA
SRI.P.SREEKUMAR, ASGI
SRI.T.C.KRISHNA, SENIOR PANEL COUNSEL
M/S.JNPS LEGAL ASSOCIATES
SRI.ARUN KUMAR.P
SRI.ABRAHAM JOSEPH MARKOS
SRI.NAVANEETH GOPAN
SRI.AMAL PARTHASARADHY, CGC
SRI.ATHUL SHAJI, SC, REGIONAL CANCER CENTRE (RCC)
SRI.V.ABRAHAM MARKOS
SRI.ISAAC THOMAS
SRI.P.G.CHANDAPILLAI ABRAHAM
SRI.ALEXANDER JOSEPH MARKOS
SRI.SHARAD JOSEPH KODANTHARA
SRI.AIBEL MATHEW SIBY
SRI.JOHN VITHAYATHIL
SRI.THIYYANNOOR RAMAKRISHNAN
SMT.AMBIKA RADHAKRISHNAN
SMT.KAVYA SURESH
SRI.ASHISH ANTONY FRANCIS
SMT.OLIVIA LEELA JACOB
SRI.GOPAKUMAR K.M.
SRI.G.SHRIKUMAR, SENIOR COUNSEL
SRI.PRAVEEN ANAND
SRI.JOSEPH KODIANTHARA, SENIOR COUNSEL
SRI.HEMANTH SINGH
SRI.T.A.SHAJI, SENIOR COUNSEL
SRI.ARJUN VENUGOPAL, CGC
SRI.RAHUL BAJAJ


THIS WRIT PETITION (CIVIL) HAVING BEEN FINALLY HEARD ON 16.09.2026, THE COURT
ON 28.09.2026 DELIVERED THE FOLLOWING:

CNR : KLHC010381092022
4
W.P.(C) No.18999 of 2022 2026:KER:74251


“C.R.”
JUDGMENT

The captioned writ petition was initially filed by a retired
Bank employee, stated to have been receiving a monthly pension
of Rs.28,400/-. Her husband is also a retired Bank employee,
receiving Rs.46,000/- as monthly pension. She was diagnosed
with HR+/HER2-Metastatic Breast Cancer being treated with
‘targeted therapy’ – CDK 4/6 inhibitors. The medicine “Ribociclib”
is stated to be one among them. The said medicine is stated to
block proteins called cyclin-dependent kinases 4/6 and thereby
slow the Cancer’s growth. This medicine is stated to be a costly
one, costing about Rs.58,140/- for 21 days (three tablets per
day). It is further stated that there are three major types of
Breast Cancer, and treatment and medicines differ for each
category. The major types are stated to be:
i. Invasive Breast Cancer
ii. Non-invasive Breast Cancer
iii. Cancerous Phyllodes Tumors.
Invasive Breast Cancer is again stated to be classified into four

CNR : KLHC010381092022
5
W.P.(C) No.18999 of 2022 2026:KER:74251


categories as under:
i. HR+/HER2 – (“Luminal A”)
ii. HR-/HER2- (“Triple Negative”)
iii. HR+/HER2+ (“Luminal B”)
iv. HR-/HER2+(“HER2-enriched”)
2. The petitioner is stated to be suffering from the first type
- Luminal A HR+/HER2-. The petitioner contends that the financial
assistance from the part of the Government for the treatment of
Breast Cancer is minimal, and that steps are required to be taken
for reducing the price of such medicines. Reference is made to
the statutory provisions under the Patents Act, 1970 (hereinafter
referred to as the ‘Act’) to contend that the Government is to
intervene with reference to the provisions under Section 92/100,
since on account of the grant of patent to the medicine, the same
is exorbitantly costly, thereby affecting the life of patients like the
petitioner. In such circumstances, the petitioner has instituted
the captioned writ petition on 02.06.2022, seeking the following
reliefs:
“i. To declare that the concerned among the respondent
nos. 1 to 3 is duty bound to take steps either under

CNR : KLHC010381092022
6
W.P.(C) No.18999 of 2022 2026:KER:74251


Section 92 or under Section 100 of the Patents Act, 1970
for Ribociclib and ensure availability of the same at a
reasonably affordable price;
ii. To issue a writ of mandamus directing the concerned
among the respondent nos.1 to 3 to take steps either
under Section 92 or under Section 100 of the Patents
Act, 1970 for Ribociclib and ensure availability and
access of the same at a reasonably affordable price;
iii. To issue a writ of mandamus directing the first respondent
to for a scheme to provide treatment for HER2-Negative
Metastatic Breast Cancer patients including the
petitioner, to provide Ribociclib at free of cost as part of
National Cancer Control Programme;
v. To issue a writ of mandamus directing the 6th respondent
to maintain the data with respect to each category of
Breast Cancer cases registered each year in India and
publish the same in the official website;”
(SIC)
3. While the writ petition was pending, the petitioner
succumbed to her illness. Taking note of the afore as well as the
submissions made by the learned counsel for the petitioner, this
Court issued the following order on 16.09.2022:
“Learned Counsel for the petitioner reports that the
petitioner has succumbed to her illness and submits that

CNR : KLHC010381092022
7
W.P.(C) No.18999 of 2022 2026:KER:74251


the noble cause espoused by the petitioner should not go
in vain.
I am also of the considered opinion that the unfortunate
death should not result in the cause espoused through this
writ petition being rendered infructuous. Therefore, this
writ petition shall continue on the board of this Court, as
a matter in which this Court has taken suo motu
cognizance on the issue of exorbitant pricing of life saving
patented medicines.
Adv.Maitreyi Sachidananda Hegde is appointed as Amicus
Curiae to assist the Court.
Registry is directed to substitute the petitioner's name as
‘ In Re Exorbitant Pricing of Life Saving Patented
Medicines’.”

4. Pending the writ petition, additional respondents 7, 10
and 15 were also permitted to be impleaded pursuant to the
orders dated 02.09.2022, 19.10.2023, and 21.08.2026,
respectively. They have joined the writ petition seeking to
support the prayers raised in the writ petition noticed earlier.
5. On 07.02.2023, this Court, noticing the prayers made
and the fact that the patented companies engaged in the
manufacture of medicines involved in this case were not made

CNR : KLHC010381092022
8
W.P.(C) No.18999 of 2022 2026:KER:74251


parties, was of the opinion that those companies are proper and
necessary parties in the writ petition, and directed the Central
Government Counsel to provide the address of the companies.
Pursuant to the said direction, two companies stated to be
engaged in the manufacture of such medicines were impleaded
as additional respondents 8 and 9 pursuant to orders dated
15.03.2023 and 16.06.2023.
6. Separate counter affidavits have also been filed by
respondents 1, 2, 3, 5, 8, 9 and 14. In the counter affidavit filed
st
by the 1 respondent, it is pointed out that another medicine,
“Palbociclib,” which is stated to have been originally manufactured
on the basis of a patent by another company, M/s.Pfizer Products
India Pvt. Ltd. is already out of the patent, on account of which
the said medicine is available at a lower and affordable price,
adding that this medicine can also be used for the treatment of
the particular type of cancer like “Ribociclib”. In other words, it
was pointed out that the afore two medicines are
interchangeable.

CNR : KLHC010381092022
9
W.P.(C) No.18999 of 2022 2026:KER:74251


7. In view of the afore, pursuant to the order dated
15.07.2026, the National Cancer Institute, Chittaranjan National
Cancer Institute, Regional Cancer Centre (RCC) and Drug
Controller General of India were also suo motu impleaded as
additional respondents 11 to 14.

8. I have heard Smt.Maitreyi Sachidananda Hegde, the
learned Amicus Curiae, Sri.P.Sreekumar, the learned Additional
Solicitor General of India (ASGI) for respondents 1, 11 and 14,
Smt.O.M.Shalina, the learned Deputy Solicitor General of India
th
for the 4 respondent, Sri.T.C.Krishna, the learned Senior Panel
Counsel for respondents 3 and 5, Sri.G.Shrikumar, the learned
Senior Counsel instructed by Sri.P.Arun Kumar and Sri.Praveen
th
Anand, the learned counsel for the 8 respondent, Sri.Joseph
Kodianthara, the learned Senior Counsel instructed by Sri.John
Vithayathil and Sri.Hemanth Singh, the learned counsel for the
th
9 respondent, Sri.T.A.Shaji, the learned Senior Counsel
instructed by Sri.Atul Shaji, the learned Standing Counsel for
RCC, as well as Sri.K.M.Gopakumar, the learned counsel for

CNR : KLHC010381092022
10
W.P.(C) No.18999 of 2022 2026:KER:74251


respondents 10 and 15, extensively.
9. Smt.Maitreyi, the learned Amicus Curiae , would submit
that:
i. Breast Cancer is one among the leading types of Cancer on
account of which many patients die. She pointed out that
every three minutes a woman is diagnosed with Breast
Cancer in India, and in every six minutes one such woman
dies. She pointed out that almost 80,000 patients diagnosed
with Breast Cancer died during 2024. She further argued
that treatment for cancer is a costly one adding that around
36% of the expenses would be the cost of medicine.
ii. She referred to the 139th report on “Cancer Care Plan and
Management: Prevention, Diagnosis, Research and
Affordability of Cancer Treatment” wherein, at paragraph
4.9.4, the Committee, having noticed that almost 40% of
cancer hospitalisation cases are being financed through
borrowings, sale of assets, etc., on account of which there is
a gap in affordability, opined that “there is a strong need to
make cancer care affordable through suitable interventions
from both Government and private sectors”.
iii. She referred to Ext.P20 study on medicine pricing issues as
per which India requires to develop a National Cancer Policy
for the prevention, diagnosis and treatment of cancer, with
specific attention to the payment required for the care.

CNR : KLHC010381092022
11
W.P.(C) No.18999 of 2022 2026:KER:74251


iv. As to whether the medicines ‘Ribociclib’ and ‘Palbociclib’ are
interchangeable, she referred to the counter affidavit of the
1st respondent dated 01.11.2022, as per which both
th
medicines are effective only as regards the IV stage of
cancer, whereas in the initial stage, Ribociclib requires to be
administered.

v. She would add that even as per the counter affidavit filed by
th
the 9 respondent and the averments in paragraphs 9 and
10, Palbociclib is a substitute only for the treatment of
advanced stages.
vi. She pointed out that the statements/affidavits filed by
respondents 11, 13 and 14 would point out that the medicine
Palbociclib can be used for treatment of advanced or
Metastatic stage of cancer.
vii. In view of the afore, it is her submission that the provisions
of Section 100 of the Act ought to have been invoked by the
Government. She would further elaborate that the patents
issued to the manufacturing companies are subject to the
general principles laid down under Section 83; when the
patents are used, and when the medicines are not made
available at affordable prices to the public, Section 100
would be attracted.
viii. She would therefore submit that the term “may” used under
Section 100 requires to be taken as “shall,” and the
Government requires to intervene. According to her, the
patients are not coming under the framework of the Act, and

CNR : KLHC010381092022
12
W.P.(C) No.18999 of 2022 2026:KER:74251


therefore the Government is considered as the
custodian/trustee of the interest of the patients, which is all
the more a reason for the Central Government to interfere.
ix. She sought to rely on the judgments of the Apex Court, this
Court as well as various judgments of the other High Courts
in support of the afore submissions.
x. She pointed out that though the deceased had filed a
representation before the Central Government, that came to
be rejected pursuant to Ext.R1(b) dated 07.10.2022, the
considerations therein being flawed.
xi. She would submit that though the writ petition was
presented also seeking relief under Section 92, insofar as
Section 92 provides for a company to come forward to seek
license thereafter, and since there is an adjudicating process
prescribed thereunder, only Section 100 of the Act is the
viable option. Therefore, she submits that the applicability
of Section 100 alone is pressed into service.

10. Sri.Rahul Bajaj, who is an intervenor in this matter
th
(additional 7 respondent), apart from adopting the submissions
made by Smt.Maitreyi sought to rely on Devika Biswas v. Union
of India and Others [(2016) 10 SCC 726] , and Mohd.
Ahmed (Minor) v. Union of India and Others [(2014) SCC
Online Del 1508] , to contend that access to life-saving

CNR : KLHC010381092022
13
W.P.(C) No.18999 of 2022 2026:KER:74251


medicines is within the ambit of the right to health under Article
21. He relied on Navtej Singh Johar and Others v. Union of
India [(2018) 10 SCC 1] to contend that the State require to
take steps to secure access to affordable patented medicines. He
relied on the judgment of the Apex Court in Gujarat Urja Vikas
Nigam Limited v. Mr.Amit Gupta and Ors.[(2021) 7 SCC
209] to contend that this Court requires to make appropriate
suggestions for making the outcome of this litigation practically
workable.
11. Sri.Gopakumar, the learned counsel for respondents
10 and 15, would submit that:
th
i. The 10 respondent is the husband of the deceased
petitioner. On account of the high price of the medicine,
the deceased was not able to afford the cost of the
medicine Ribociclib.
th
ii. The 15 respondent, a Breast Cancer patient, is also a
lawyer who is to spend around Rs.7.90 lakhs every year
towards the medicine Ribociclib.
iii. The per capita income in India is Rs.2.19 lakhs, and this
itself is a pointer to show that the medicine Ribociclib is not
affordable for the majority of the population.

CNR : KLHC010381092022
14
W.P.(C) No.18999 of 2022 2026:KER:74251


iv. Though respondents 8 and 9 are speaking much about the
research and development expenditure, details thereof are
not provided by them.
v. Patent under the Act is a conditional one.
vi. The State has a duty under Article 47 of the Constitution of
India to improve public health.

12. Sri.Sreekumar, the learned ASGI, would contend that:
i. The question as to whether Section 92/100 of the Act
requires to be invoked has been considered in extenso by
the Central Government as evidenced by Ext.R1(b) order
dated 07.10.2022.
ii. Though the writ petition has been instituted contending
that the medicine is not affordable, no required data is
provided.
iii. He would add that Section 92 is applicable only in the
circumstances stated thereunder and not in any other
circumstances.
iv. As regards Section 100, it is contended that the same is
attracted when an invention requires to be “used” for the
“purposes of Government” and not in a situation like the
case herein.

13. Smt.O.M.Shalina, the learned Deputy Solicitor General
th
of India (DSGI), appeared on behalf of the 4 respondent and

CNR : KLHC010381092022
15
W.P.(C) No.18999 of 2022 2026:KER:74251


would contend that:
i. The prayer made in the writ petition is for the issuance of a
writ of mandamus. However, it is not demonstrated that a
request to invoke the provisions under Section 100 of the
Act was made before the Government; hence, the
mandamus cannot be issued.
ii. As regards the invocation of Section 92 of the Act, the
Government has issued Ext.R1(b) after examining all the
aspects, which has not been challenged by anyone.
iii. She further adds that this Court could not mould a relief
and set aside Ext.R1(b) without there being any challenge
to the same.
iv. She refers to the provisions of the Drugs (Price Control)
Order, 2013, (for short, the ‘Order’) framed by the
Government under the enabling provisions of the Essential
Commodities Act, 1955, to state that the medicine
Ribociclib is a non-scheduled drug and, under paragraph 20
of the order, the Government has been monitoring the price
of the same and has also capped the price.
v. Even the provisions of paragraph 32 of the afore Order
providing for non-application of the provisions of the Order
would not apply to the medicine in question since the
respective companies do not have a case that the same is
developed through “indigenous Research and
Development”.
vi. The Government has already reduced the basic customs

CNR : KLHC010381092022
16
W.P.(C) No.18999 of 2022 2026:KER:74251


duty for the medicine Ribociclib with effect from
01.02.2026, on account of which, the price for 21 tablets
during January and March at Rs.24,355/- came down to
Rs.22,217.85 during April and thereafter went again
upward to Rs. 22,335/- during July.
vii. He sought to place considerable reliance on the judgment
of the Karnataka High Court in W.P.No.11057 of 2019 dated
30.11.2022, to state that the writ court is not to interfere
with the policy decision of the Government.

14. Sri.Krishna, the learned Senior Panel Counsel, would
contend that:
i. Section 100 of the Act starts with a non-obstante clause;
the same requires to be enforced “for the purposes of
Government” in accordance with the provisions of Chapter
XVII of the Act.
ii. Therefore, he would state that the meaning of the term
“use of invention for the purposes of Government” is to be
read along with Section 99 under Chapter XVII.

15. Sri.Kodianthara, the learned Senior Counsel, instructed
th
by Sri.John Vithayathil, the learned counsel for the 9 respondent
company, which manufactures the medicine “Ribociclib” on the
basis of the patent, would contend that:

CNR : KLHC010381092022
17
W.P.(C) No.18999 of 2022 2026:KER:74251


i. Section 100 can be invoked only when the patent requires to
be used exclusively “for the purposes of Government”. He
refers to the provisions of Section 99 of Chapter XVII, and
states that, the meaning of the term “use of invention for the
purposes of Government” having been separately laid down
under Section 99, the prayer made in the writ petition is not
to be granted. In other words, he states that Section 100 is
applicable only to cases where the Central Government
requires the use of the patent “for the purposes of
Government”, and not in an instance where the Government
is informed that there is a requirement for reduction of the
price.
ii. He sought to rely on the principles laid down by a learned
Single Judge of the Nagpur Bench of the Bombay High Court
in Garware Wall Ropes Ltd., Pune v. M/s A.I.Chopra,
Engineers and Contractors, Nagpur and another
[(2008) SCC OnLine BOM 1225] in this regard.
iii. With reference to the averments in paragraph 15 of the
th
counter affidavit filed by the 9 respondent, it is pointed out
that, among various countries, the said respondent is
charging the lowest price in India.

iv. He makes reference to a notification issued by the National
Pharmaceutical Pricing Authority pursuant to which a 30%
cap on the trade margin on Ribociclib has been imposed, on
account of which, it is clear that the Government has already
intervened so as to regulate the price of the medicine.

CNR : KLHC010381092022
18
W.P.(C) No.18999 of 2022 2026:KER:74251


v. Without prejudice, he referred to the opinion of respondents
11, 13 and 14 that the medicine Palbociclib is a substitute for
Ribociclib, and contended that the prayers in the writ petition
are purely academic.

16. Sri.Hemant Singh, who also made submissions on
th
behalf of the 9 respondent, would contend that:
th
i. The 9 respondent has invented the medicine Ribociclib
through a long process involving failed trials/inventions,
innovations, investing huge amounts in human resources,
research and development, and the research and
development as above is only being encouraged by
extending the full protection by granting patent.
ii. The protection through a patent, is actually a quid pro quo
pursuant to which the patentee discloses the innovation
to the public and, on the expiry of the patent, the
technology can be used by the public.

iii. In view of the afore, it is his submission that pricing is not
to be a criterion for denying/restricting a patent.
iv. Section 100 requires to be read along with the provisions
of Section 156 also, and therefore, the patent binds the
Government just like any other individual.
v. With reference to the statistics provided in paragraph 14
th
of the counter affidavit filed by the 9 respondent, he
states that CDK 4/6 inhibitors like Ribociclib are being

CNR : KLHC010381092022
19
W.P.(C) No.18999 of 2022 2026:KER:74251


used only by 13% of total Breast Cancer patients and the
rest of the patients go for various other treatment options
like chemotherapy, chemo plus Endocrine therapy,
Endocrine therapy, etc. Therefore, he would add that the
price of Ribociclib by itself cannot be a reason for
invocation of the provisions of Section 100 of the Act.

vi. He would further state that what requires to be done is
the detection of Breast Cancer at the early stage itself so
that the same does not become a life-threatening one,
when in India nearly 60% cases are diagnosed at a later
stage of the disease, which makes the treatment difficult.

17. Sri.G.Shrikumar, the learned Senior Counsel instructed
th
by Sri.Arun Kumar, the learned counsel for the 8 respondent,
would contend that:
i. Originally in India it was only the “process” that was being
patented, and at present it is the “product” that is being
th
patented, and hence, the patent of the 8 respondent
requires to be protected.
ii. He would state that the 8th respondent is manufacturing
the medicine “Abemaciclib” which is also mentioned in
various statements/reports/opinions of respondents 11, 13
and 14 as CDK 4/6 inhibitor for treatment of Metastatic
Breast Cancer. He contends that since there was no prayer
as regards the afore medicine qua the provisions of the Act,

CNR : KLHC010381092022
20
W.P.(C) No.18999 of 2022 2026:KER:74251


th
the 8 respondent’s patent is not to be disturbed.
iii. He relied on the Single Bench judgment of this Court in
Aravindan K.P. (Dr.) v. Union of India [2022 KHC
Online 7761] , the judgment of the Division Bench of this
Court in W.P(C) No.29182 of 2009, the judgment of the
Apex Court in Distribution of Essential Supplies and
Services During Pandemic, In Re [(2021) 18 SCC
201] , etc., in support of the afore.


th
18. Sri.Praveen Anand, the learned counsel for the 8
respondent, also made submissions as under:
i. The amounts spent on the inventions/research cannot be
overlooked, and such investment is also being protected
under the Act.
th
ii. The 8 respondent applied for a patent in 2008 and has been
granted the same only in 2018, on account of which, it has
protection only for another 10 years from 2018, which in
effect is only 50% of the total protection.

iii. He relied on the averments contained in paragraph 52 of the
counter affidavit to point out that the company is offering
free-of-charge medicines after the initial 9 months of
therapy and for early Breast Cancer patients one pack of
Ramiven® is offered free of charge for the entire duration of
therapy upon purchase of three packs.
19. Sri.T.A.Shaji, the learned Senior Counsel instructed by

CNR : KLHC010381092022
21
W.P.(C) No.18999 of 2022 2026:KER:74251


th
Sri.Atul Shaji, the learned Standing Counsel for the 13
respondent (RCC), also made submissions. He would invite the
attention of this Court to a report dated 20.08.2026 from the
RCC, as per which the three medicines “Palbociclib, Ribociclib and
Abemaciclib" are the three available medicines for treatment of
stage IV Breast Cancer.
20. I have considered the rival contentions as well as the
connected records.
21. Before proceeding to consider the submissions made
on the applicability of Section 100 of the Act, the question as to
whether the medicine “Palbociclib” can be used as a substitute for
“Ribociclib” requires to be considered. The learned Amicus Curiae
has emphatically pointed out that “Palbociclib” can only be used
in the advanced stages, whereas “Ribociclib” is being
administered at the early stages.

22. In this regard, the counter affidavit filed by the
th
additional 14 respondent dated 14.08.2026 requires to be
noticed. In the said affidavit, with reference to the details

CNR : KLHC010381092022
22
W.P.(C) No.18999 of 2022 2026:KER:74251


available with that office, it is pointed out that Palbociclib is used
in the treatment of “advanced or Metastatic Breast Cancer”.
However, as regards Ribociclib, it is pointed out that the same is
th
being used for “early Breast Cancer”. The additional 13
respondent (RCC) in its report dated 20.08.2026 has also pointed
out that “Palbociclib” is being administered for “stage IV” Breast
Cancer. The expert opinion as above shows that “Palbociclib” and
“Ribociclib” are not interchangeable.
23. In the light of the afore, this Court proceeds to consider
the submissions made with respect to the applicability of Section
100 of the Act.
24. The main issue arising for consideration is as to
whether the Central Government requires to intervene with
reference to the provisions of Section 100 of the Act. As already
noticed, the learned Amicus Curiae contends that the Government
has to intervene and use the invention for its purposes, and such
a direction requires to be issued by this Court. Section 100 of
the Act reads as under:

CNR : KLHC010381092022
23
W.P.(C) No.18999 of 2022 2026:KER:74251


“ 100. Power of Central Government to use inventions
for purposes of Government .—(1) Notwithstanding
anything contained in this Act, at any time after an
application for a patent has been filed at the patent office
or a patent has been granted, the Central Government and
any person authorised in writing by it, may use the
invention for the purposes of Government in accordance
with the provisions of this Chapter.


(2) Where an invention has, before the priority date of the
relevant claim of the complete specification, been duly
recorded in a document, or tested or tried, by or on behalf
of the Government or a Government undertaking,
otherwise than in consequence of the communication of the
invention directly or indirectly by the patentee or by a
person from whom he derives title, any use of the invention
by the Central Government or any person authorised in
writing by it for the purposes of Government may be made
free of any royalty or other remuneration to the patentee.

(3) If and so far as the invention has not been so recorded
or tried or tested as aforesaid, any use of the invention
made by the Central Government or any person authorised
by it under sub-section (1), at any time after grant of the
patent or in consequence of any such communication as
aforesaid, shall be made upon terms as may be agreed

CNR : KLHC010381092022
24
W.P.(C) No.18999 of 2022 2026:KER:74251


upon either before or after the use, between the Central
Government or any person authorised under sub-section
(1) and the patentee, or, as may in default of agreement
be determined by the High Court on a reference under
section 103:
Provided that in case of any such use of any patent, the
patentee shall be paid not more than adequate
remuneration in the circumstances of each case, taking into
account the economic value of the use of the patent.

(4) The authorisation by the Central Government in respect
of an invention may be given under this section, either
before or after the patent is granted and either before or
after the acts in respect of which such authorisation is given
or done, and may be given to any person, whether or not
he is authorised directly or indirectly by the applicant or the
patentee to make, use, exercise or vend the invention or
import the machine, apparatus or other article or medicine
or drug covered by such patent.

(5) Where an invention has been used by or with the
authority of the Central Government for the purposes of
Government under this section, then, except in case of
national emergency or other circumstances of extreme
urgency or for non-commercial use, the Government shall
notify the patentee as soon as practicable of the fact and

CNR : KLHC010381092022
25
W.P.(C) No.18999 of 2022 2026:KER:74251


furnish him with such information as to the extent of the
use of the invention as he may, from time to time,
reasonably require; and where the invention has been used
for the purposes of a Government undertaking, the Central
Government may call for such information as may be
necessary for this purpose from such undertaking.

(6) The right to make, use, exercise and vend an invention
for the purposes of Government under sub-section (1) shall
include the right to sell, on non-commercial basis, the
goods which have been made in exercise of that right, and
a purchaser of goods so sold, and a person claiming
through him, shall have the power to deal with the goods
as if the Central Government or the person authorised
under sub-section (1) were the patentee of the invention.

(7) Where in respect of a patent which has been the subject
of an authorisation under this section, there is an exclusive
licensee as is referred to in sub-section (3) of section 101,
or where such patent has been assigned to the patentee in
consideration of royalties or other benefits determined by
reference to the use of the invention (including payments
by way of minimum royalty), the notice directed to be given
under sub-section (5) shall also be given to such exclusive
licensee or assignor, as the case may be, and the reference
to the patentee in sub-section (3) shall be deemed to

CNR : KLHC010381092022
26
W.P.(C) No.18999 of 2022 2026:KER:74251


include a reference to such assignor or exclusive licensee.”

True, Section 100 of the Act begins with a non-obstante clause.
However, it requires to be noticed further that the Central
Government or any person authorised in writing by it is permitted
to “use the invention for the purposes of Government” in
accordance with the provisions of Chapter XVII. Therefore, even
on the face of the non-obstante clause, the provisions of Section
99 of the Act providing for a meaning for the term “use of
invention for the purposes of Government” requires to be noticed,
which reads as follows:
“ 99. Meaning of use of invention for purposes of
Government .—(1) For the purposes of this Chapter, an
invention is said to be used for the purposes of
Government if it is made, used, exercised or vended for
the purposes of the Central Government, a State
Government or a Government undertaking.

(2)
(3) Nothing contained in this Chapter shall apply in
respect of any such importation, making or using of any
machine, apparatus or other article or of any such using
of any process or of any such importation, using or

CNR : KLHC010381092022
27
W.P.(C) No.18999 of 2022 2026:KER:74251


distribution of any medicine or drug, as may be made by
virtue of one or more of the conditions specified in section
47.”
It is also to be further seen that Chapter XVII, under which
Sections 99 and 100 are provided, provides for “use of invention
for the purposes of Government” and the acquisition of invention
by the Central Government.
25. Therefore, under Section 99 of the Act, an invention is
said to be used for the purposes of Government if the same is
made, used, exercised or vended for the purposes of Central
Government, State Government or a Government undertaking. In
other words, the patent/invention requires to be used by the
Government alone under the provisions of Section 100 read with
the provisions of Section 99. Here, the prayer made is for a
direction to the Government to invoke Section 100 so that the
invention by the patent holder is used for safeguarding the
interest of the public at large.
26. The learned ASGI, the learned DSGI, and the learned
Senior Counsel for respondents 8 and 9, as already noticed,

CNR : KLHC010381092022
28
W.P.(C) No.18999 of 2022 2026:KER:74251


contended that the provisions of Section 100 of the Act would not
apply since the same could be invoked only for the purposes of
Government and for no other reasons. In other words, according
to them, invoking Section 100, the Government cannot
manufacture the medicine using the inventions which have been
patented by respondents 8 and 9 and thereafter supply the same
to the needy patients free of cost or at subsidised price. At first
blush, the said submission appears attractive, especially in light
of the provisions under Section 99, which defines the term “use
of invention for the purposes of Government” as stipulated
thereunder.
27. However, the matter requires to be considered with
reference to the various subsections under Section 100 also. For
instance, sub-section (4) entitles the Government to authorise
any person to
i. Make
ii. Use
iii. Exercise, or
iv. Vend

CNR : KLHC010381092022
29
W.P.(C) No.18999 of 2022 2026:KER:74251


the invention or import of the machine, apparatus or other article
or “medicine or drug” covered by such patent. Similarly, sub-
section (6) also makes it clear that the right to make, use,
exercise and vend an invention shall include the right to sell, on
non-commercial basis, the goods which have been made in
exercise of that right. In view of the afore provisions, this Court
is of the opinion that the term “for the purposes of Government”
requires to be interpreted also taking into account the right to
vend/sell the goods made using the patent and invention on a
non-commercial basis to a purchaser. The provisions of Section
100 impose no restriction on who the purchaser could be. When
that be so, the provisions under Section 100 would include the
entitlement of the Government to use the patent or invention for
manufacturing the medicine covered by the patent and sell the
same on a non-commercial basis to a person who can be none
other than the needy patient. This position is made further clear
by the specific inclusion of “medicines or drugs” under sub-section
(4).

CNR : KLHC010381092022
30
W.P.(C) No.18999 of 2022 2026:KER:74251


28. Considerable reliance was placed on the judgment of the
Nagpur Bench of the Bombay High Court in Garware Wall Ropes
Ltd . ( supra ) by the respondents (the Government and the
Companies) to state that the term “purposes of Government” is
having a restrictive meaning. The operative portion of the afore
judgment needs to be noticed as under:
“21. Perusal of the above provisions show that the said
terminology ‘merely of its own use’ has been deliberately
used in Section 47 of the Act in contrast to the provisions
of Sections 99 and 100 of the Patents Act, viz. for the
purposes of Government, for the purposes of Central
Government, State Government or Government
undertaking. The words ‘merely of its own use’ have been
utilized with a definite purpose and it cannot be said that
the Parliament used different words in Sections 47, 99 and
100 of the Act for no reasons or for no intentions. In my
opinion, all these words 'merely of its own use’ would mean
use for the purposes of the Government by any department
of the Government and use by servants and agents of the
Government in performance of their duties/in discharge of
their duties assigned to them irrespective of who is
benefited by such use. This would not include use by any
other person like contractor of railways and the meaning is

CNR : KLHC010381092022
31
W.P.(C) No.18999 of 2022 2026:KER:74251


strictly restricted to the direct use by any department of
the Government or its servants in the performance/in the
discharge of their duties. This is all the more so, because
for such use contemplated by Section 47 of the Act, no
payment of royalty is at all contemplated to the patentee.
In terms of the doctrine of ‘eminent domain’
Parliament/Government is entitled to make a patent
subject to such conditions as are to be found in Section 47
of the Act. In a similar manner a look at Sections 35 to 42
contained in Chapter VII of the Act will reveal that for the
security and defence of India all rights of the patentees
have been curtailed as the same is a sovereign function.
No patentee can claim a right on a high pedestal than the
Government performing sovereign function.
22. It is, thus, clear from the above provisions of Sections
99 and 100 of the Act that by using the words ‘for the
purposes of Government' as against 'merely of its own use’
in Section 47 of the Act, the use of inventions stands
extended even to the Central Government, State
Government or a Government Undertaking. According to
me, these provisions have been made in order that the
patents can be utilized by Central Government, State
Government for the purposes other than purely
departmental in the discharge of duties or the sovereign
functions but in accordance with the terms and conditions
laid down in this Chapter XVII. Under these provisions

CNR : KLHC010381092022
32
W.P.(C) No.18999 of 2022 2026:KER:74251


even a third person i.e. contractor like respondent No.1 can
be allowed to use the patent for the purposes of
Government or Government undertakings. But then that is
upon the agreement or licence given by the patentee to
such third person and upon, of-course, the payment of
royalty etc. It is clear to me that the Central Government
or State Government are not entitled to use a patent free
of cost as already held by me for any other purposes than
'merely of its own use’ i.e. for performing the
Governmental functions by the Government servants or
Government departments in performance of their duties or
in the discharge of their duties. The mechanism, therefore,
provided by Chapter XVII is to allow even the third party,
Central Government and State Government (for use other
than 'merely of its own use').”
(Underlining supplied)
True, the Bombay High Court held that the term “purposes of
Government” can only be of meaning: purposes of Government
by any department of the Government and use by servants and
agents of the Government in performance/discharge of their
duties. However, it is necessary to notice the distinction, as
observed by the Bombay High Court, between the provisions of
Section 100 and Section 47 of the Act, which uses the words

CNR : KLHC010381092022
33
W.P.(C) No.18999 of 2022 2026:KER:74251


“merely of its own use”. The term “purposes of Government” also
includes the vending of articles made using the invention, as laid
down under sub-sections (4) and (6) of Section 100, as discussed
earlier, and the same cannot be disputed in view of the clear
language.
29. Article 47 of the Constitution of India has laid down that
the State has a duty to improve public health, being a primary
duty of the State.
30. Therefore, the term “purposes of Government” also
includes the duty of the Government/State to improve public
health as mandated under Article 47 of the Constitution of India.
This has to include the use of the patent, manufacturing of the
medicines, and supplying the same on a non-commercial basis
under Section 100(6) of the Act to the needy patients. The
Nagpur Bench of the Bombay High Court has also, in paragraph
22 of the afore judgment, held that the provisions under Section
100 as well as Section 47 have been made so that the patents
can be utilised by the Central/State Government for purposes

CNR : KLHC010381092022
34
W.P.(C) No.18999 of 2022 2026:KER:74251


other than purely departmental in the discharge of duties or the
sovereign functions.
31. The reliance placed by the Government as well as
respondents 8 and 9 on the judgment of the Apex Court in
Distribution of Essential Supplies and Services During
Pandemic, In Re ( supra ) may also not be apposite, since the
Apex Court also, in paragraphs 46 and 47 of the afore judgment,
with reference to Section 100 of the Act, found as under:
“46. …….. Further, under Section 100 of the Patents Act,
the Central Government can authorise certain companies
to use any patents for the “purpose of the Government”.
Indian companies can begin manufacturing the drugs
while negotiating the royalties with the patentees. If the
Central Government or its authorised company is not able
to reach an agreement with the patentee, the High Court
has to fix the reasonable royalty that is to be paid to the
patentee. ……………

47. The utilisation of these flexibilities has also been
detailed in the Trade Related Aspects of Intellectual
Property Rights Agreement (“TRIPS”). Even as TRIPS
obliges countries to ensure a minimum level of patent
protection, it creates a permissive regime for the carving

CNR : KLHC010381092022
35
W.P.(C) No.18999 of 2022 2026:KER:74251


out of exceptions and limitations that further public health
objectives. This is evident from a conjoint reading of
Articles 7, 8, 30 and 31 of TRIPS. Article 7 outlines the
objectives of the TRIPS as being to ensure the effective
enforcement of intellectual property in a way that, inter
alia, is “conducive to social and economic welfare”. Article
8 gives member countries the freedom to take measures
that protect public health and nutrition. Article 8(2) allows
for the taking of TRIPS-compatible measures aimed at
preventing the abuse of intellectual property rights.
Articles 30 and 31 deal with exceptions to the rights of
patent owners, by allowing grant of compulsory licences.
It leaves countries with significant breathing space to
determine how the compulsory licensing or government-
use levers can be triggered. While such determinations
must be made on the individual merits of each case, the
aforesaid caveat does not apply when the compulsory
licence grant is for national emergency, extreme urgency
or public non-commercial use.”
(Underlining supplied)
Therefore, the Apex Court has also held that Section 100 is
required to be enforced in the interest of the public at large,
particularly to ensure the protection of patients. Reference also
needs to be made to the provisions of Articles 7/8 of TRIPS,

CNR : KLHC010381092022
36
W.P.(C) No.18999 of 2022 2026:KER:74251


wherein it is made clear that the very aim of providing intellectual
property rights is for the “mutual advantage of producers and
users” alike and also to empower the member nations to “adopt
measures necessary to protect public health and nutrition”.
32. The matter also requires to be approached with
reference to the mandate under Article 21 of the Constitution of
India. The right to self-preservation of one's life is to be accorded
paramount importance by virtue of the mandate under Article 21.
In Pt. Parmanand Katara v. Union of India and Others
[(1989) 4 SCC 286] , the Apex Court has categorically
reiterated about the duty of the Government for preservation of
life in the following lines:
“7. There can be no second opinion that preservation of
human life is of paramount importance. That is so on
account of the fact that once life is lost, the status quo ante
cannot be restored as resurrection is beyond the capacity
of man. The patient whether he be an innocent person or
be a criminal liable to punishment under the laws of the
society, it is the obligation of those who are in charge of
the health of the community to preserve life so that the
innocent may be protected and the guilty may be punished.

CNR : KLHC010381092022
37
W.P.(C) No.18999 of 2022 2026:KER:74251


Social laws do not contemplate death by negligence to
tantamount to legal punishment.
8. Article 21 of the Constitution casts the obligation on the
State to preserve life. The provision as explained by this
Court in scores of decisions has emphasised and reiterated
with gradually increasing emphasis that position. A doctor
at the government hospital positioned to meet this State
obligation is, therefore, duty bound to extend medical
assistance for preserving life. Every doctor whether at a
government hospital or otherwise has the professional
obligation to extend his services with due expertise for
protecting life. No law or State action can intervene to
avoid/delay the discharge of the paramount obligation cast
upon members of the medical profession. The obligation
being total, absolute and paramount, laws of procedure
whether in statutes or otherwise which would interfere with
the discharge of this obligation cannot be sustained and
must, therefore, give way.”

33. Again, the Apex Court in Paschim Banga Khet
Mazdoor Samity and Others v. State of W.B. and Another
[(1996) 4 SCC 37] spoke about the Government’s duty to
consider the preservation of life as having paramount importance
in the following lines:

CNR : KLHC010381092022
38
W.P.(C) No.18999 of 2022 2026:KER:74251


“9. The Constitution envisages the establishment of a
welfare State at the federal level as well as at the State
level. In a welfare State the primary duty of the
Government is to secure the welfare of the people.
Providing adequate medical facilities for the people is an
essential part of the obligations undertaken by the
Government in a welfare State. The Government
discharges this obligation by running hospitals and
health centres which provide medical care to the person
seeking to avail of those facilities. Article 21 imposes an
obligation on the State to safeguard the right to life of
every person. Preservation of human life is thus of
paramount importance. ………
………..
16. It is no doubt true that financial resources are
needed for providing these facilities. But at the same
time it cannot be ignored that it is the constitutional
obligation of the State to provide adequate medical
services to the people. Whatever is necessary for this
purpose has to be done. In the context of the
constitutional obligation to provide free legal aid to a
poor accused this Court has held that the State cannot
avoid its constitutional obligation in that regard on
account of financial constraints. [See: Khatri (II) v. State
of Bihar , SCC at p. 631.] The said observations would
apply with equal, if not greater, force in the matter of

CNR : KLHC010381092022
39
W.P.(C) No.18999 of 2022 2026:KER:74251


discharge of constitutional obligation of the State to
provide medical aid to preserve human life. In the
matter of allocation of funds for medical services the said
constitutional obligation of the State has to be kept in
view. It is necessary that a time-bound plan for
providing these services should be chalked out keeping
in view the recommendations of the Committee as well
as the requirements for ensuring availability of proper
medical services in this regard as indicated by us and
steps should be taken to implement the same. The State
of West Bengal alone is a party to these proceedings.
Other States, though not parties, should also take
necessary steps in the light of the recommendations
made by the Committee, the directions contained in the
memorandum of the Government of West Bengal dated
22-8-1995 and the further directions given herein.

17. The Union of India is a party to these proceedings.
Since it is the joint obligation of the Centre as well as the
States to provide medical services, it is expected that the
Union of India would render the necessary assistance in
the improvement of the medical services in the country
on these lines.”

34. The Apex Court in Vincent Panikurlangara v. Union
of India and Others [(1987) 2 SCC 165] has considered an

CNR : KLHC010381092022
40
W.P.(C) No.18999 of 2022 2026:KER:74251


issue regarding withdrawal of licenses of manufacturers of drugs
which are injurious and harmful to the life of patients and held as
under:
“16. A healthy body is the very foundation for all human
activities. That is why the adage “ Sariramadyam
Khaludharma Sadhanam ”. In a welfare State, therefore,
it is the obligation of the State to ensure the creation and
the sustaining of conditions congenial to good health.
This Court in Bandhua Mukti Morcha v. Union of India
aptly observed: (SCC p. 183, para 10)
It is the fundamental right of everyone in this
country, assured under the interpretation given
to Article 21 by this Court in Francis Mullin case
to live with human dignity, free from
exploitation. This right to live with human dignity
enshrined in Article 21 derives its life breath
from the Directive Principles of State Policy and
particularly clauses (e) and (f) of Article 39 and
Articles 41 and 42 and at the least, therefore, it
must include protection of the health and
strength of the workers, men and women, and
of the tender age of children against abuse,
opportunities and facilities for children to
develop in a healthy manner and in conditions of
freedom and dignity, educational facilities, just

CNR : KLHC010381092022
41
W.P.(C) No.18999 of 2022 2026:KER:74251


and humane conditions of work and maternity
relief. These are the minimum requirements
which must exist in order to enable a person to
live with human dignity and no State — neither
the Central Government nor any State
Government — has the right to take any action
which will deprive a person of the enjoyment of
these basic essentials.

While endorsing what has been said above, we would
refer to Article 47 in Part IV of the Constitution. That
article provides:
The State shall regard the raising of the level of
nutrition and the standard of living of its people
and the improvement of public health as among
its primary duties and, in particular, the State
shall endeavour to bring about prohibition of the
consumption except for medicinal purposes of
intoxicating drinks and of drugs which are
injurious to health.
This article has laid stress on improvement of public
health and prohibition of drugs injurious to health as one
of the primary duties of the State. In Akhil Bharatiya
Soshit Karamchari Sangh v. Union of India this Court has
pointed out that: (SCC pp. 308-09, para 123)

The fundamental rights are intended to foster
the ideal of a political democracy and to

CNR : KLHC010381092022
42
W.P.(C) No.18999 of 2022 2026:KER:74251


prevent the establishment of authoritarian rule
but they are of no value unless they can be
enforced by resort to courts. So they are made
justiciable. But, it is also evident that
notwithstanding their great importance, the
Directive Principles cannot in the very nature of
things be enforced in a court of law.... It does
not mean that directive principles are less
important than fundamental rights or that they
are not binding on the various organs of the
State.
In a series of pronouncements during the recent years
this Court has culled out from the provisions of Part IV
of the Constitution these several obligations of the State
and called upon it to effectuate them in order that the
resultant pictured by the Constitution Fathers may
become a reality. As pointed out by us, maintenance and
improvement of public health have to rank high as these
are indispensable to the very physical existence of the
community and on the betterment of these depends the
building of the society of which the Constitution makers
envisaged. Attending to public health, in our opinion,
therefore, is of high priority — perhaps the one at the
top.

17. None of the parties before us claimed, and perhaps
rightly, that the prevailing state of affairs in this regard

CNR : KLHC010381092022
43
W.P.(C) No.18999 of 2022 2026:KER:74251


is a commendable one. The technical aspects which arise
for consideration in a matter of this type cannot be
effectively handled by a court. Similarly the question of
policy which is involved in the matter is also one for the
Union Government — keeping the best of interests of
citizens in view to decide. No final say in regard to such
aspects come under the purview of the court. Yet there
are certain contentions raised by the petitioner which
deserve serious consideration and we would now proceed
to deal with them.”
(Underlining supplied)

Therefore, there can be no doubt that the Government is required
to provide all necessary facilities to citizens to ensure access to
healthcare, including access to life-saving treatment, as in the
case at hand. As pointed out in the case at hand, the high cost
of the drug in question virtually defeats the requirements under
Articles 21 and 47 of the Constitution of India. This is because,
as already noticed, the “purposes of Government” would
encompass the mandate contained in Articles 21 and 47 referred
to above.
35. Again, a reference also requires to be made to the

CNR : KLHC010381092022
44
W.P.(C) No.18999 of 2022 2026:KER:74251


provisions under Section 83 of the Act, the relevant portions of
which read as under:
“ 83. General principles applicable to working of
patented inventions .—Without prejudice to the other
provisions contained in this Act, in exercising the powers
conferred by this Chapter, regard shall be had to the
following general considerations, namely:—
………….
(d) that patents granted do not impede protection of public
health and nutrition and should act as instrument to
promote public interest specially in sectors of vital
importance for socio-economic and technological
development of India;
(e) that patents granted do not in any way prohibit Central
Government in taking measures to protect public health;

………….
(g) that patents are granted to make the benefit of the
patented invention available at reasonably affordable
prices to the public.”

(Underlining supplied)
Therefore, the fact that the patent granted is subject to the right
of the Government to promote public health and the public
interest has been made very clear by the incorporation of the

CNR : KLHC010381092022
45
W.P.(C) No.18999 of 2022 2026:KER:74251


above caveat. Further sub-section (g) also speaks about the
requirement/duty to provide patented inventions at reasonably
affordable prices to the public.
36. At this juncture, the submissions made by Smt.Maitreyi
with reference to the Lok Sabha debates in connection with the
Patent (Amendment) Bill, 2002 also require to be noticed. In
response to certain apprehensions by the Parliamentarians, it has
been clarified that under the provisions of Section 100 of the Act,
the Government can use the patent at any time “in the interest
of the public health system”. It is further clarified that the
Government can “procure it and sell it to the hospitals or they can
give it to third parties”. Therefore, the intention behind the
provisions of Section 100 is also made clear as noticed above.
37. In the light of the afore, this Court is of the opinion that
the provisions of Section 100 of the Act are required to be invoked
in circumstances where the Government is required to intervene,
such as when the medicine is unaffordable on account of its
exorbitant price.

CNR : KLHC010381092022
46
W.P.(C) No.18999 of 2022 2026:KER:74251


38. Even on the face of the afore, the question arises as to
whether this Court is to issue a positive direction to the
Government to exercise the power under Section 100 of the Act
as interpreted above. This is particularly so since there can be
no dispute that the patent has been granted in recognition of the
new invention relating to the medicine in question. Such a grant
of a patent extends utmost protection to the patent holder so that
he can utilize the same commercially. On account of the
protection as above, the patent holder enjoys an exclusion of any
other person from using the invention, till such time validity of
the patent continues. Even the Government is bound by the
patent, as has been clearly stated in Section 156 of the Act. If
such sanctity is not being extended to a patentee, that would be
a factor which would be counterproductive insofar as no one will
come forward to register their patent under the statute. If this
happens, the inventions would not be used by anyone, which is
detrimental to the interest of the society at large. It is in the light
of the afore that Parliament sought to enact the statute,

CNR : KLHC010381092022
47
W.P.(C) No.18999 of 2022 2026:KER:74251


regulating and consolidating the law relating to patents in the
year 1970, more particularly on the basis of the recommendations
of the Justice N.Rajagopala Ayyangar Committee. The statute so
consolidated aims at protecting the process leading to the
manufacture of the article by patenting the same.
39. In the light of the afore, it is for the Central Government
to consider whether Section 100 of the Act requires to be invoked
since ultimately the same is a policy decision.
40. True, the Apex Court in Distribution of Essential
Supplies and Services During Pandemic, In Re ( supra ), has
found that Section 100 of the Act requires to be invoked in
appropriate circumstances as discussed therein. At the same
time, after finding so, the Apex Court has further found as under:
“49. Whether and if so, the extent to which these
provisions should be utilised is a policy decision for the
Central Government. We have flagged the issue for its
consideration. We have only outlined the legal framework
within which the Central Government can possibly
consider compulsory licensing and government acquisition
of patents. The Central Government is free to choose any

CNR : KLHC010381092022
48
W.P.(C) No.18999 of 2022 2026:KER:74251


other course of action that it deems fit to tackle the issue
of vaccine requirements in an equitable and expedient
manner, which may involve negotiations with domestic
and foreign producers of vaccines. We clarify that it is up
to the Central Government to choose the best possible
measures it can undertake during the current crisis
keeping in mind that public interest is of paramount
importance.”

(Underlining supplied)
Thus, it is for the Central Government to consider whether Section
100 requires to be invoked after collecting the necessary
statistics.
41. The Apex Court, again in State of Punjab v. Ram
Lubhaya Bagga [(1998) 4 SCC 117] , has found as under:
“25. Now we revert to the last submission, whether the new
State policy is justified in not reimbursing an employee,
his full medical expenses incurred on such treatment, if
incurred in any hospital in India not being a government
hospital in Punjab. Question is whether the new policy
which is restricted by the financial constraints of the State
to the rates in AIIMS would be in violation of Article 21 of
the Constitution of India. So far as questioning the validity
of governmental policy is concerned in our view it is not
normally within the domain of any court, to weigh the pros

CNR : KLHC010381092022
49
W.P.(C) No.18999 of 2022 2026:KER:74251


and cons of the policy or to scrutinize it and test the
degree of its beneficial or equitable disposition for the
purpose of varying, modifying or annulling it, based on
howsoever sound and good reasoning, except where it is
arbitrary or violative of any constitutional, statutory or
any other provision of law. When Government forms its
policy, it is based on a number of circumstances on facts,
law including constraints based on its resources. It is also
based on expert opinion. It would be dangerous if court is
asked to test the utility, beneficial effect of the policy or
its appraisal based on facts set out on affidavits. The court
would dissuade itself from entering into this realm which
belongs to the executive. It is within this matrix that it is
to be seen whether the new policy violates Article 21 when
it restricts reimbursement on account of its financial
constraints.
26. When we speak about a right, it correlates to a duty
upon another, individual, employer, government or
authority. In other words, the right of one is an obligation
of another. Hence the right of a citizen to live under Article
21 casts obligation on the State. This obligation is further
reinforced under Article 47, it is for the State to secure
health to its citizen as its primary duty. No doubt the
Government is rendering this obligation by opening
government hospitals and health centres, but in order to
make it meaningful, it has to be within the reach of its

CNR : KLHC010381092022
50
W.P.(C) No.18999 of 2022 2026:KER:74251


people, as far as possible, to reduce the queue of waiting
lists, and it has to provide all facilities for which an
employee looks for at another hospital. Its upkeep,
maintenance and cleanliness has to be beyond aspersion.
To employ the best of talents and tone up its
administration to give effective contribution. Also bring in
awareness in welfare of hospital staff for their dedicated
service, give them periodical, medico-ethical and service-
oriented training, not only at the entry point but also
during the whole tenure of their service. Since it is one of
the most sacrosanct and valuable rights of a citizen and
equally sacrosanct sacred obligation of the State, every
citizen of this welfare State looks towards the State for it
to perform its this obligation with top priority including by
way of allocation of sufficient funds. This in turn will not
only secure the right of its citizen to the best of their
satisfaction but in turn will benefit the State in achieving
its social, political and economical goal. For every return
there has to be investment. Investment needs resources
and finances. So even to protect this sacrosanct right
finances are an inherent requirement. Harnessing such
resources needs top priority.”

To the same effect are the principles laid down in Brij Mohan Lal
v. Union of India [(2012) 6 SCC 502] (Paragraphs 96 and 99).

CNR : KLHC010381092022
51
W.P.(C) No.18999 of 2022 2026:KER:74251



42. This is especially so, since this Court is of the opinion
that the required data to decide whether the particular medicines
in question are affordable or not, has not been brought on record.
The data requires to be collected by the Government, as to the
actual number of persons affected with the particular type of
cancer, the number of patients consuming the medicines in
question, the cases where such medicines are not consumed by
patients on account of the alleged exorbitant price, etc., by
collecting such details from the hospitals across the country. It
also requires to be noticed that, as contended by some of the
respondents, the Government itself is stated to have introduced
various schemes for supplying medicines at subsidised prices, etc.
But the number of patients who have been benefited from such
schemes requires to be evaluated. The Government is also
required to consider the effectiveness of such schemes and
whether they require to be extended any further, especially since
it is pointed out by the Government and the companies that the

CNR : KLHC010381092022
52
W.P.(C) No.18999 of 2022 2026:KER:74251


cancer medicines are brought under price control with reference
to the capping of the price as noticed above. Further, the findings
in the judgment as regards the scope of Section 100 of the Act
would have applicability as against several other life saving drugs
also. However, only the manufacturers of two such medicines are
before this Court, and submissions were made on that basis
alone. Therefore, it is for the Government to ponder as regards
the requirement to invoke Section 100 in appropriate cases after
collecting the required data.
43. More recently, the Apex Court in Siddharth Dalmia v.
Union of India [2025 (3) KHC 349 (SC)] has considered the
question as to whether the affairs of the private hospital with
reference to pricing of drugs, equipment, etc. could be regulated,
as under:-
“14. In this backdrop, would it be prudent for the Union
of India or the States to introduce a policy which
regulates each and every activity within the compound
of these private hospitals? Will such a policy discourage
persons to come forward and invest in the health
industry throughout the country? Most importantly, why

CNR : KLHC010381092022
53
W.P.(C) No.18999 of 2022 2026:KER:74251


should the States not adopt such economic policies
whereunder they ensure dedicated apportionments
towards the development of basic infrastructure,
including institutions for health services; and till such
time the States are able to do so, whether stringent
measures which would stall private entities from
coming forward, should be allowed to be introduced?

15. All these issues are undoubtedly of paramount
public importance. It, however, seems to us that such
issues primarily involve policy decisions, for which the
policy-makers are the best equipped to take a holistic
view and formulate the guidelines as may be required
(In Re: S.6A of the Citizenship Act 1955, 2024 SCC
OnLine SC 2880; Suman Kumar v. Union of India, [2023
SCC OnLine SC 1750; Transport & Dock Workers Union
v. Mumbai Port Trust, [2011 (2) SCC 575]; Govt. of A.P.
v. N. Subbarayudu, [2008 (14) SCC 702], to safeguard
the patients or their attendants from exploitation while
simultaneously, ensuring that there is no
discouragement and unreasonable restriction on private
entities from entering the health sector.

16. It may be noticed that the subject of public health
and sanitation, hospitals, and dispensaries falls under
List-II - the State List - and, therefore, any such

CNR : KLHC010381092022
54
W.P.(C) No.18999 of 2022 2026:KER:74251


measure, as illustrated above, must be taken by the
State Governments, keeping their local conditions in
mind.
17. To sum up, it may not be advisable for this Court to
issue mandatory directions which may hamper the
growth of hospitals in the private sector; but parallelly,
it is necessary to sensitize the State Governments re:
the problem of unreasonable charges and exploitation
of patients in private hospitals.”
(Underlining supplied)
Therefore, ultimately it is for the Central Government to consider
the question as to whether Section 100 of the Act requires to be
invoked with reference to the factual position.
th
44. The 139 Report by the Department-Related
Parliamentary Standing Committee on Health and Family Welfare
on Cancer Care Plan and Management: Prevention, Diagnosis,
Research and Affordability of Cancer Treatment published during
September, 2022 also requires to be noticed. In the report of the
Committee, after deliberation on the matter, has observed as
under:-

“4.9.4 The Committee has been apprised that one among

CNR : KLHC010381092022
55
W.P.(C) No.18999 of 2022 2026:KER:74251


the five cancer insurance claims is by patient belonging to
36 to 45 years of age, thereby resulting into the loss or
disruption of household income. As per the National
Sample Survey Healthcare even average out of pocket
spending on cancer care is too high. The out of pocket
spending for cancer care in private facilities is about three
times that of public facilities. About 40% of cancer
hospitalization cases are financed mainly through
borrowings, sale of assets and contributions from friends
and relatives. Considering such a glaring gap in
affordability when it comes to quality cancer care, the
Committee feels that there is a strong need to make cancer
care affordable through suitable interventions from both
Government and private sectors.”
It is for the Government to take note of the above and move
forward accordingly.

In the result, I dispose of this writ petition with the following
findings:
i. Provisions under Section 100 of the Act would also
include the entitlement of the Government to use the
patent or invention for manufacturing the medicine
covered by the patent and sell the same to a person,
including a needy patient, on a non-commercial basis.

CNR : KLHC010381092022
56
W.P.(C) No.18999 of 2022 2026:KER:74251


ii. Section 100 of the Act is required to be invoked in
circumstances where the Government is required to
intervene, such as an instance where a medicine
manufactured on the basis of a patent is being sold at an
exorbitant price.
iii. The Government requires to collate the required data

and arrive at a decision as to whether a particular
medicine is affordable or not and, on that basis, proceed
in accordance with Section 100 of the Act, if found
necessary.
Before parting, I must also place on record the appreciation
for the efforts, erudition, good grounding in legal principles and
industry of Smt.Maitreyi Sachidananda Hegde, the learned
Amicus Curiae , which was of much assistance to this Court.

EPILOGUE

Jnanpith Laureate and Padma Vibhushan awardee, late
M.T.Vasudevan Nair, who was also a renowned screenplay writer
in his highly acclaimed work “Sukrutham”, has depicted, with
great force, the plight of not just the patients of this despicable
disease but also of their bystanders. In the film directed by

CNR : KLHC010381092022
57
W.P.(C) No.18999 of 2022 2026:KER:74251


Sri.Harikumar, the protagonist, portrayed by the legendary
Padma Bhushan awardee Sri.Mammootty, can be seen informing
his doctor that he won’t be opting for the injunction. He follows
this with a heartbreaking monologue on how cancer patients and
their bystanders end up pledging their entire lives to afford proper
medical care, only to be left buried in mountains of debt. It is
highly distressing that despite the passage of more than three
decades since this story was adapted into the movie vocabulary,
and won accolades at the National and State levels, and despite
the growth of technology, the plight of patients and their families
remains the same. The aim of art was, is, and always will be to
bring the various realms of society closer and to make them more
aware of the lives led by others. Yet, despite such heavy social
cavalry, society and the situation have been stuck at a standstill
in such cases. The Government, the people, and stakeholders
should, as a joint venture, ensure that no man is refused or
refuses treatment exclusively due to financial constraints. It is
imperative that, we, as a community and as a system that caters

CNR : KLHC010381092022
58
W.P.(C) No.18999 of 2022 2026:KER:74251


to billions, strike the balance between affordable access to
medical treatment and maintaining adequate incentives.

Sd/-

HARISANKAR V.MENON
JUDGE
ln

CNR : KLHC010381092022
59
W.P.(C) No.18999 of 2022 2026:KER:74251


APPENDIX OF WP(C) NO.18999 OF 2022


PETITIONER’S EXHIBITS:

EXHIBIT P1 SEALED COVER

EXHIBIT P2 SEALED COVER

EXHIBIT P3 TRUE COPY OF THE NEWS ITEM DATED 08.03.2021 WITH
THE TITLE 'NEW GLOBAL BREAST CANCER INITIATIVE
HIGHLIGHTS RENEWED COMMITMENT TO IMPROVE SURVIVAL'
APPEARED IN THE OFFICIAL WEBSITE OF THE WHO.

EXHIBIT P4 TRUE COPY OF THE PAPER WITH THE TITLE OVERVIEW OF
BREAST CANCER AND IMPLICATIONS OF OVERTREATMENT OF
EARLY-STAGE BREAST CANCER: AN INDIAN PERSPECTIVE’,
DATED 08.06.2020 PUBLISHED IN JCO GLOBAL ONCOL
6:789-798. © 2020 BY AMERICAN SOCIETY OF CLINICAL
ONCOLOGY.

EXHIBIT P5 TRUE COPY OF THE ARTICLE BY DR. SADHANA KALA DATED
26.10.2020 PUBLISHED IN TIMES OF INDIA.

EXHIBIT P6 TRUE COPY OF THE PRESS RELEASE DATED 18.08.2020
ISSUED BY INDIAN COUNCIL OF MEDICAL RESEARCH ALONG
WITH NATIONAL CANCER REGISTRY PROGRAMME.

EXHIBIT P7 TRUE COPY OF THE LETTER DATED 03.06.2021, AUTHORED
BY AMOL PATEL, TVSGK TILAK, VINEET G GUPTA, ATUL
BATRA, PRASHANT MEHTA, PURVISH PARIKH AND HEMANT
MALHOTRA 'DYNAMICS OF SEQUENCING OF CYCLIN-
DEPENDENT KINASE INHIBITORS AND COST EXPENDITURE
ANALYSIS IN THE MANAGEMENT OF METASTATIC HORMONE-
RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR
2-NEGATIVE ADVANCED BREAST CANCER' PUBLISHED IN
INDIAN JOURNAL OF MEDICAL AND PEDIATRIC ONCOLOGY.

EXHIBIT P8 TRUE COPY NEWS REPORT DATED 19.09.2022 FROM THE
WEBSITE OF NOVARTIS, MANUFACTURER OF RIBOCICLIB.

EXHIBIT P9 TRUE COPY OF THE REPORT FROM THE WEBSITE OF U.S.

CNR : KLHC010381092022
60
W.P.(C) No.18999 of 2022 2026:KER:74251


FOOD AND DRUG ADMINISTRATION.

EXHIBIT P10 TRUE COPY OF THE REPORT FROM THE WEBSITE
CHEMOCARE.COM, AN ORGANISATION WORKING IN THE
FIELD OF CANCER MEDICINE.

EXHIBIT P11 TRUE COPY OF THE E-REGISTER OF THE PATENT NUMBER
283133 DOWNLOADED FROM THE OFFICIAL WEBSITE OF THE
5TH RESPONDENT.

EXHIBIT P12 TRUE COPY OF THE RELEVANT PAGES OF THE COPY OF THE
WORKING PAPER 490 AUTHORED BY SUDIP CHAUDHURI
TITLED 'HOW EFFECTIVE HAS BEEN GOVERNMENT MEASURES
TO CONTROL PRICES OF ANTI- CANCER MEDICINES IN
INDIA?'PUBLISHED BY CENTRE FOR DEVELOPMENT
STUDIES, THIRUVANANTHAPURAM, KERALA IN DECEMBER,
2019.

EXHIBIT P13 TRUE COPY OF THE FORM 27 PERTAINING TO THE PATENT
NO. 283133 FOR THE YEAR 2018 DOWNLOADED FROM THE
OFFICIAL WEBSITE OF THE 5TH RESPONDENT.

EXHIBIT P14 TRUE COPY OF THE FORM 27 PERTAINING TO THE PATENT
NO. 283133 FOR THE YEAR 2019 DOWNLOADED FROM THE
OFFICIAL WEBSITE OF THE 5TH RESPONDENT.

EXHIBIT P15 TRUE COPY OF THE FORM 27 PERTAINING TO THE PATENT
NO. 283133 FOR THE YEAR 2020 DOWNLOADED FROM THE
OFFICIAL WEBSITE OF THE 5TH RESPONDENT.

EXHIBIT P16 TRUE COPY OF THE FORM 27 PERTAINING TO THE PATENT
NO. 283133 FOR THE YEAR 2021 DOWNLOADED FROM THE
OFFICIAL WEBSITE OF THE 5TH RESPONDENT.

EXHIBIT P17 TRUE COPY OF THE REPORT PUBLISHED IN DECEMBER, 2019
BY U.S.FOOD & DRUG ADMINISTRATION, AUTHORED BY RYAN
CONARD, RANDALL LUTTER WITH THE TITLE 'GENERIC
COMPETITION AND DRUG PRICES: NEW EVIDENCE LINKING
GREATER GENERIC COMPETITION AND LOWER GENERIC DRUG
PRICES'.

EXHIBIT P18 TRUE COPY OF THE BREAST CANCER (AWARENESS AND FREE
TREATMENT) BILL, 2017.

CNR : KLHC010381092022
61
W.P.(C) No.18999 of 2022 2026:KER:74251



EXHIBIT P19 TRUE COPY OF THE RELEVANT PAGES OF THE REPORT BY
THE HIGH-LEVEL EXPERT GROUP ON UNIVERSAL HEALTH
COVERAGE FOR INDIA.

EXHIBIT P20 TRUE COPY OF THE RELEVANT PAGES OF THE REPORT
PREPARED BY ELLEN T HOEN FOR OXFAM INTERNATIONAL,
WITH THE TITLE 'ACCESS TO CANCER TREATMENT - A
STUDY OF MEDICINE PRICING ISSUES WITH
RECOMMENDATIONS FOR IMPROVING ACCESS TO CANCER
MEDICATION' (2014).

EXHIBIT P21 TRUE COPY OF THE SAME PAPER TITLED 'COMPULSORY
LICENSES FOR CANCER DRUGS: DOES CIRCUMVENTING
PATENT RIGHTS IMPROVE ACCESS TO ONCOLOGY
MEDICATIONS?'.

EXHIBIT P22 TRUE COPY OF THE INFORMATION PUBLISHED BY THE PRESS
INFORMATION BUREAU, MINISTRY OF COMMERCE AND
INDUSTRY ON 19.12.2014.

EXHIBIT P23 TRUE COPY OF THE DRUGS (PRICES CONTROL) AMENDMENT
ORDER, 2019 DATED 03.01.2019.

EXHIBIT P24 TRUE COPY OF THE NOTIFICATION DATED 27.02.2019
DOWNLOADED FROM THE OFFICIAL WEBSITE OF THE
NATIONAL PHARMACEUTICAL PRICING AUTHORITY.

EXHIBIT P25 SEALED COVER

RESPONDENTS’ EXHIBITS

EXHIBIT R1(A) TRUE COPY OF THE MINUTES OF THE MEETING DATED
26.08.2022.

EXHIBIT R1(B) TRUE COPY OF THE ORDER NO. P-24013(14)/1/2022-/PR-
III DATED 07.10.2022.

EXHIBIT-R8(A) TRUE COPY OF THE PRINTOUT OF THE PATENT CERTIFICATE
OF ELI LILY IN 760 DATED 19.06.2018.

EXHIBIT-R8(B) TRUE COPY OF THE COMPLETE SPECIFICATION OF IN 760

CNR : KLHC010381092022
62
W.P.(C) No.18999 of 2022 2026:KER:74251


DATED 19.05.2011.

EXHIBIT-R8(C) TRUE COPY OF THE E-REGISTER.

EXHIBIT-R8(D) TRUE COPY OF THE ORDER DATED JUNE 19, 2020, IN CS
COMM 183 OF 2020.

EXHIBIT-R8(E) TRUE COPY OF THE PATENTS ACT, 1970 AT LENGTH IN
RE: DISTRIBUTION OF ESSENTIAL SUPPLIES AND
SERVICES DURING PANDEMIC, SUO MOTU WRIT PETITION
(CIVIL) NO.3 OF 2021 (AIR-2022 PAGE NO.2356).

EXHIBIT-R8(F) TRUE COPY OF THE WORKING STATEMENT FILED BEFORE
THE INDIAN PATENT OFFICE. FOR INSTANCE, FOR THE
YEAR 2020-21, ABEMACICLIB WORTH INR 4,33,00,000
WAS IMPORTED AND FOR THE YEAR 2021-22, ABEMACICLIB
WORTH INR 21,32,00,000 WAS IMPORTED INTO INDIA.
FORMS 27 AS FILED BEFORE THE INDIAN PATENT OFFICE.

EXHIBIT-R8(G) TRUE COPY OF THE ONLINE ARTICLES, RESEARCH PAPERS
BASED ON THE TUFTS CENTER FOR THE STUDY AND DRUG
DEVELOPMENT ON DRUG DISCOVERY AND DEVELOPMENT, AND
ARTICLES ON CLINICAL TRIALS FOR NEW DRUGS.

EXHIBIT R9(A) TRUE COPY OF THE POWER OF ATTORNEY EXECUTED BY THE
ADDITIONAL RESPONDENT NO.9 IN FAVOUR OF THE
DEPONENT.

EXHIBIT R9(B) TRUE COPY OF WHITE PAPER DATED 23.10.2018 ON BREAST
CANCER LANDSCAPE IN INDIA.

EXHIBIT R9(C) TRUE COPY OF US FOOD AND DRUGS ADMINISTRATION
(USFDA) FOR ABEMACICLIB.

EXHIBIT R9(D) TRUE COPY OF US FOOD AND DRUGS ADMINISTRATION
(USFDA) FOR PALBOCICLIB.

EXHIBIT R9(E) TRUE COPY OF US FOOD AND DRUGS ADMINISTRATION
(USFDA) FOR RIBOCICLIB.

EXHIBIT R9(F) TRUE COPY OF RESEARCH PAPER TITLED BREAST CANCER
IN INDIA PRESENT SCENARIO AND THE CHALLENGES AHEAD,
BY MEHROTRA R, YADAV K, DATED 24.03.2022.

CNR : KLHC010381092022
63
W.P.(C) No.18999 of 2022 2026:KER:74251



EXHIBIT R9(G) TRUE COPY OF PRESS RELEASE BY ADDITIONAL RESPONDENT
NO.9 DATED 09.09.2022.

EXHIBIT R9(H) TRUE COPY OF LIST OF ALL GENERIC PALBOCICLIC DRUG
PRODUCTS AVAILABLE IN THE INDIAN MARKET AS ON
28.07.2023.

EXHIBIT R9(I) TRUE COPY OF LIST OF ALL DRUGS APPROVED FOR
TREATMENT OF BREAST CANCER AS AVAILABLE ON THE
OFFICIAL WEBSITE OF NATIONAL CANCER INSTITUTE.

EXHIBIT R9(J) TRUE COPY OF EXTERNAL MARKET DATA REPORT DATED
15.06.2023 PROVIDED TO NOVARTIS HEALTHCARE LIMITED
BY COGNITREX CONSULTANTS PRIVATE LIMITED.

EXHIBIT R9(K) TRUE COPY OF ADDITIONAL RESPONDENT NO.9S CURRENT
PRICING CIRCULAR FOR RIBOCICLIB.

EXHIBIT R9(L) TRUE COPY OF THE DRUGS (PRICES CONTROL) ORDER 2013
DATED 15.05.2013.

EXHIBIT R9(M) TRUE COPY OF NATIONAL PHARMACEUTICALS PRICING
AUTHORITY (NPPA) NOTIFICATION DATED 27.02.2019.

EXHIBIT R9(N) TRUE COPY OF NATIONAL PHARMACEUTICALS PRICING
AUTHORITY (NPPA) NOTIFICATION DATED 28.02.2020.

EXHIBIT R9(O) TRUE COPY OF WEBSITE EXTRACTS OF ADDITIONAL
RESPONDENT NO. 9 HIGHLIGHTING NOVARTIS POSITION ON
ACCESS TO MEDICINES.

EXHIBIT R9(P) TRUE COPY OF ADDITIONAL RESPONDENT 9S BROCHURE OF
UMAANG PROGRAM.

EXHIBIT R9(Q) TRUE COPY OF WEBSITE EXTRACTS OF KMSCL AND KARUNYA
COMMUNITY SCHEME.

EXHIBIT R9(R) TRUE COPY OF FORM 27 DATED 20.09.2022 FILED BY
NOVARTIS FOR INDIAN PATENT NO.283133.

EXHIBIT R10A A TRUE COPY OF THE LETTER DATED 19.04.2026 WRITTEN

CNR : KLHC010381092022
64
W.P.(C) No.18999 of 2022 2026:KER:74251


BY DR.RAVI KANNAN TO THIS HON’BLE COURT.


ANNEXURE R13(A) TRUE COPY OF THE REPORT DATED 20.08.2026.

EXHIBIT R15(A) A TRUE COPY OF THE DISCHARGE SUMMARY ALREADY
PRODUCED ALONG WITH MY AFFIDAVIT DATED 18.08.2026,
FILED IN I.A. NO.1 OF 2026.

EXHIBIT R15(B) A TRUE COPY OF THE REPRESENTATIVE BILL DATED
16.09.2025 ISSUED BY THE MVR CANCER CENTRE AND
RESEARCH INSTITUTE.

EXHIBIT R15(C) A TRUE COPY OF THE AFFIDAVIT BY MY TREATING DOCTOR
DATED 30.08.2026.

EXHIBIT R15(D) A TRUE COPY OF THE RELEVANT PAGE OF THE NOVARTIS
ANNUAL REPORT 2022.

EXHIBIT R15(E) A TRUE COPY OF THE RELEVANT PAGE OF THE NOVARTIS
ANNUAL REPORT 2025.

RESPONDENTS’ ANNEXURES

ANNEXURE I COPY OF THE PRESS RELEASE DATED 19.02.2016 FROM
THE OFFICIAL WEBSITE OF PFIZER WITH THE TITLE
'PFIZER RECEIVES EXPANDED FDA APPROVAL FOR IBRANCE
(PALBOCICLIB) IN HR, HER2- METASTATIC BREAST
CANCER'.

ANNEXURE II COPY OF THE FDA APPROVAL NOTIFICATION DATED
03.03.2023 FROM THE OFFICIAL WEBSITE OF FDA WITH
THE TITLE 'FDA EXPANDS EARLY BREAST CANCER
INDICATION FOR ABEMACICLIB WITH ENDOCRINE
THERAPY'.

ANNEXURE III COPY OF THE FDA APPROVAL NOTIFICATION DATED
17.09.2024 FROM THE OFFICIAL WEBSITE OF FDA WITH
THE TITLE 'FDA APPROVES RIBOCICLIB WITH AN
AROMATASE INHIBITOR AND RIBOCICLIB AND LETROZOLE
CO-PACK FOR EARLY HIGH-RISK BREAST CANCER'


CNR : KLHC010381092022
65
W.P.(C) No.18999 of 2022 2026:KER:74251


ANNEXURE IV COPY OF THE STUDY TITLED 'REAL-WORLD EFFECTIVENESS
COMPARISON OF FIRST-LINE PALBOCICLIB, RIBOCICLIB
OR ABEMACICLIB PLUS ENDOCRINE THERAPY IN ADVANCED
HR-POSITIVE/HER2-NEGATIVE BC PATIENTS: RESULTS
FROM THE MULTICENTER PALMARES-2 STUDY', PUBLISHED
IN ANNALS OF ONCOLOGY, VOLUME 36, ISSUE 7, 2025.